MOUNTAIN VIEW, Calif., Oct. 31 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services designed to optimize clinical drug development, announced today that Rene Bruno, Ph.D., Managing Director, Strategic Consulting Services, Europe, will speak to members of the pharmaceutical and biotechnology industries attending the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, to be held at the Gaylord Opryland Resort and Convention Center in Nashville, Tennessee, November 6-10, 2005.
Dr. Bruno will present in the Pharmacokinetics, Pharmacodynamics and Drug Metabolism Track, along with panelists from industry and the FDA, in an AAPS/ACCP joint symposium on “Getting The Dose Right: Model-Based Drug Development in Oncology.” The session will include applications of model-based clinical pharmacology in oncology and will describe research on how modeling and simulation has been used to predict expected clinical outcomes and support decision-making during early development. The session will also describe research on how dosing has been optimized for specific patient populations in oncology, and will offer a regulatory perspective on use of model-based drug development in the drug approval process. Additional information can be found at www.aaps.org.
About Pharsight Corporation
Pharsight Corporation develops and markets products and services that help pharmaceutical and biotechnology companies improve their decision-making in drug development and commercialization. By integrating scientific, clinical and business decision criteria into a dynamic, model-based methodology, Pharsight helps its customers optimize the value of their drug development programs and portfolios from discovery to post-launch marketing and any point in between. Pharsight uses computer-based drug-disease models, dynamic predictive market models, clinical trial simulation and advanced valuation models to create a continuously evolving view of its customers’ development efforts and product portfolios. This enables decision makers to make explicit value-driven trade-offs throughout the development and commercialization process. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available on the World Wide Web at www.pharsight.com.
Pharsight Corporation
CONTACT: investors, Douglas Sherk, +1-415-896-6820, or JenniferBeugelmans, +1-415-896-6820, or media, Steve DiMattia, +1-917-620-0590, allof EVC Group, for Pharsight Corporation
